40+ years of excellence in custom synthesis and bioconjugation services.
Calculators, design tools, and educational content to support your research.
Bridged, non-bridged and flexible sugar-modified XNA chemistries for higher binding affinity, controlled duplex flexibility, improved mismatch discrimination, enhanced nuclease resistance, and advanced antisense, splice-switching, diagnostic and hybridization applications.
Advanced sugar-modified xenonucleic acids (XNAs) are synthetic nucleic acid analogs in which the native ribose or deoxyribose sugar has been chemically engineered to alter conformation, flexibility, duplex stability and biological performance. These modifications can improve hybridization affinity, nuclease resistance and mismatch discrimination, or deliberately introduce local flexibility where reduced duplex stability is advantageous.
Bio-Synthesis manufactures oligonucleotides containing LNA, BNA, ENA, cEt, 2'‑O‑NMA, 2'‑AmNA and UNA for antisense gapmers, splice-switching oligonucleotides, hybridization probes, qPCR assays, molecular diagnostics and therapeutic research. These chemistries span bridged or conformationally constrained sugars, non-bridged 2' sugar modifications and flexible unlocked sugars, so the best choice depends on the intended mechanism and application.
LNA, BNA, ENA, cEt and 2'-AmNA for conformational preorganization and affinity enhancement.
2'-O-NMA for high-affinity sugar engineering without a covalent bridge.
UNA for local flexibility, duplex destabilization and structural tuning.
ASO, SSO, qPCR, SNP detection, hybridization and therapeutic research.
Design note: These sugar-modified XNAs are not interchangeable. LNA, BNA, ENA, cEt and 2'‑AmNA are used primarily for conformational preorganization and affinity enhancement; 2'‑O‑NMA is a distinct non-bridged sugar modification; and UNA increases local flexibility and generally lowers duplex stability. Selection should consider target biology, RNase H compatibility, desired affinity or flexibility, delivery strategy and assay requirements.
The seven chemistries sit along a functional spectrum. Some strongly preorganize the sugar for affinity and stability, while others preserve or introduce flexibility to tune duplex behavior.
A covalent bridge or related structural constraint preorganizes the sugar into a preferred geometry. This generally supports stronger target binding, higher duplex stability and improved resistance to enzymatic degradation.
How the strategy works
Structural restriction reduces the conformational freedom required for duplex formation and preorganizes the modified residue for target recognition.
Design watchpoint
High modification density can over-stabilize a duplex, alter specificity or affect biological behavior, so placement should remain sequence- and application-specific.
Primary Effect
Typical Benefit
Common Use
The 2′ position is modified without forming a bridge, providing a distinct way to tune affinity, stability and biological behavior.
Opening the sugar ring creates a highly flexible analog that can lower local duplex stability and tune structure, specificity or strand asymmetry.
How to read this map: LNA is a specific bridged nucleic acid, while BNA is the broader family designation. The position of each family reflects its primary structural behavior, not a universal performance ranking.
Choose the primary design objective to see which sugar-modified XNA chemistries are commonly considered and what tradeoffs should be reviewed.
These chemistries strongly preorganize the sugar and are commonly used when the primary goal is to increase affinity toward RNA or DNA while maintaining a conventional oligonucleotide format.
Design Priorities
Main Caution
Maximum affinity is not always maximum specificity.
Bridged and constrained sugars can improve resistance to nuclease-mediated degradation. The optimal chemistry depends on sequence, backbone, biological matrix, delivery and safety requirements.
Higher nuclease resistance does not guarantee better cellular delivery.
High-affinity constrained sugars are commonly placed in the wings of DNA-gap antisense oligonucleotides to support target binding while preserving an RNase H-compatible central gap.
Fully modified constrained oligos may not recruit RNase H.
Splice-switching oligonucleotides rely on target occupancy rather than cleavage. Constrained and next-generation sugar chemistries can increase affinity, stability and pharmacological performance.
High affinity cannot compensate for an inaccessible splice target.
LNA/BNA and related sugar-modified XNA chemistries can raise probe Tm, shorten probe length and improve mismatch discrimination when placed near weak or discriminating positions.
Over-stabilization can reduce SNP discrimination.
Therapeutic programs should balance potency, safety, target engagement, tissue distribution, delivery, manufacturability and analytical control rather than selecting solely by duplex affinity.
The chemistry with the highest affinity may not have the best safety profile.
Use this guide as an initial screening tool. Final chemistry selection should be confirmed against sequence, mechanism, target accessibility, backbone, delivery and analytical requirements.
Select a chemistry to compare its structural concept, affinity or flexibility profile, nuclease resistance, preferred applications and practical design considerations.
LNA uses a 2'-O,4'-C methylene bridge to lock the ribose in an RNA-like conformation. It is one of the most established high-affinity sugar modifications for antisense gapmers, probes and mismatch discrimination.
Affinity
Flexibility
Best Known For
BNA is a broader structural family of nucleic acid analogs in which the sugar is conformationally restricted by an intramolecular bridge. LNA is one important member of this family, while other BNA architectures use different bridge chemistries.
ENA uses an ethylene bridge that constrains the sugar and supports strong RNA binding, nuclease resistance and RNase H-compatible gapmer designs when used in the flanks.
cEt is a high-affinity bridged sugar used in antisense and short-oligo designs. It can support potent target engagement and compact architectures, but modification density and sequence-dependent safety require careful review.
2'-O-NMA is a distinct non-bridged 2' sugar modification. It belongs on this broader sugar-modified XNA page, but it should not be described as a bridged or strictly constrained nucleic acid.
2'-AmNA is a conformationally constrained amino-modified nucleic acid analog. Its restricted sugar geometry supports affinity enhancement and nuclease resistance, while its amino functionality provides a distinct chemical profile from 2'-O-NMA.
UNA removes the C2'–C3' bond of the ribose ring, creating a highly flexible acyclic sugar analog. Unlike the affinity-enhancing bridged chemistries, UNA generally lowers duplex stability and is used to tune flexibility, accessibility and mismatch behavior.
The star ratings provide relative, application-oriented guidance rather than universal performance claims. Results depend on sequence, modification density, placement, backbone, target, assay format and biological context.
★★★★★ Excellent / leading fit ★★★★☆ Very good ★★★☆☆ Moderate ★★☆☆☆ Limited ★☆☆☆☆ Minimal ☆☆☆☆☆ Not typically used
Important: BNA is a family designation rather than one single monomer structure. The BNA column reflects the broader platform, while the LNA column describes the specific 2′-O,4′-C-methylene chemistry. Star ratings should be treated as comparative design guidance, not as guaranteed performance.
Sugar-modified XNAs are often used as one component of a broader design rather than as a standalone solution.
Common gapmer architecture for RNase H-active antisense oligonucleotides.
High-affinity antisense and short-oligo designs with sequence-specific review.
Affinity-enhanced qPCR, dPCR, FISH and imaging probes.
Emerging SSO and therapeutic research with peptide, lipid or ligand delivery.
Explore the four coordinated chemistry platforms used to engineer the backbone, sugar scaffold and nucleobase-recognition system of next-generation oligonucleotides.
→
Affinity, modification density, target mechanism, synthesis feasibility, purification, analytical QC and scale-up needs.
Advanced sugar-modified XNA projects require controlled synthesis, purification, analytical review and project-specific documentation.
Bio-Synthesis supports LNA, BNA, ENA, cEt, 2'‑O‑NMA, 2'‑AmNA and UNA programs with controlled synthesis, purification, analytical QC, documentation and project-specific packaging.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.